The importance of minimal residual disease for detection of late relapse in Bprecursor acute lymphoblastic leukemia.
Hippokratia
; 26(1): 38-40, 2022.
Article
em En
| MEDLINE
| ID: mdl-37124277
ABSTRACT
BACKGROUND:
The minimal residual disease (MRD) level in patients with B-precursor acute lymphoblastic leukemia (B-ALL) is the strongest independent predictor of relapse and survival. Assessment of MRD plays a crucial role in the treatment of B-ALL. CASE REPORT We performed long-term monitoring of a 30-year-old woman with B-ALL of standard risk for MRD using multiparametric flow cytometry (MFC). After five years of monitoring, molecular relapse of the disease was confirmed.CONCLUSION:
This case illustrates that more extended monitoring for MRD, even by only MFC when other newer sophisticated diagnostics are not available, is essential in detecting early relapse in patients with B-ALL of standard risk. HIPPOKRATIA 2022, 26 (1)38-40.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Tipo de estudo:
Diagnostic_studies
/
Prognostic_studies
Idioma:
En
Revista:
Hippokratia
Ano de publicação:
2022
Tipo de documento:
Article